Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leucettinib-21 in Healthy Volunteers and Subjects With Down Syndrome or Alzheimer's Disease
NCT06206824Phase 1Completed
- Sponsor
- Perha Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of leucettinib-21 in Down syndrome and Alzheimer's disease (AD) (6 arms), sponsored by Perha Pharmaceuticals. Primary endpoints: Safety and tolerability of Leucettinib-21 at 21 days and Pharmacokinetics of Leucettinib-21 at 24 hours. Started Jan 2024; status: completed.
02
Drugs
leucettinib-21
03
Conditions
Down syndromeAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06206824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206824.